ArticleThe Journal of biological chemistry2026
Alpha-cell glucagon is essential for maintaining β-cell function and identity in adult mice.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have analyzed the effect of glucagon on β-cells and glucose homeostasis, either by ablating α-cells or by globally deleting the glucagon/glucagon receptor gene. To investigate possible interactions between α-cells and β-cells, and the effect of α-cells on β-cells/glucose homeostasis, we generated mouse models to allow deletion of the glucagon gene in α-cells (acute-α-GCG-KO) and the glucagon receptor gene in β-cells of adult mice. Specific deletion of the glucagon gene in the α-cell in adult mice led to impaired glucose tolerance, reduced β-cell mass and function, islet inflammation, β-cell endoplasmic reticulum stress, and altered β-cell ultrastructure. Notably, these detrimental effects were reversed by exogenous glucagon administration, but not by the glucagon-like peptide-1 analog exendin-4, indicating that glucagon deficiency specifically harms β-cells. Interestingly, acute ablation of α-cells in acute-α-GCG-KO mice reversed the alteration in glucose homeostasis and in β cells, suggesting that α-cells lacking glucagon gene expression can negatively impact β-cells, perhaps by some unknown factor(s). To investigate the role of the β-cell's glucagon receptor on the observed effect of glucagon gene deletion, we specifically deleted the glucagon receptor gene in β-cells, either congenitally or acutely in the adult mouse; here, there were no changes in β-cells and glucose homeostasis, suggesting that the effect of glucagon on β-cells can be mediated via other signaling pathways. Conclusion: Glucagon gene deletion in α-cells of adult mice is detrimental to β-cells, and this effect is reversed by glucagon administration, suggesting that glucagon deficiency is specifically injurious to β-cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.